^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    busulfan

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    3d
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    4d
    Cord Blood Transplantation in Children and Young Adults With Blood Cancer (clinicaltrials.gov)
    P2, N=71, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A)
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • cyclosporine
    4d
    COSI: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (clinicaltrials.gov)
    P2/3, N=333, Active, not recruiting, University of Birmingham | Trial completion date: Mar 2025 --> May 2026 | Trial primary completion date: Mar 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • thiotepa • busulfan
    5d
    Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Sawa Ito, MD
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan
    6d
    TBF-AML: TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission (clinicaltrials.gov)
    P=N/A, N=93, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    fludarabine IV • thiotepa • busulfan
    10d
    Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov)
    P2, N=177, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    fludarabine IV • busulfan
    10d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Recruiting, University of Birmingham | Active, not recruiting --> Recruiting
    Enrollment open
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    13d
    CEREAL: Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes (clinicaltrials.gov)
    P1, N=29, Recruiting, Institut Paoli-Calmettes | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cladribine • fludarabine IV • busulfan
    15d
    ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, San Rocco Therapeutics | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2025 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    busulfan • Neupogen (filgrastim)
    18d
    Erjing Wan ameliorates busulfan-induced oligoasthenospermia in mice by inhibiting p38 MAPK/NF-κB pathway (PubMed, Zhongguo Zhong Yao Za Zhi)
    In conclusion, EJW extracts ameliorate Bu-induced oligoasthenospermia by inhibiting the p38 MAPK/NF-κB signaling pathway and mitigating testicular oxidative stress and inflammatory responses. The active material basis is likely associated with flavonoids and steroidal saponins in the alcohol extract, as well as polysaccharides.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    busulfan
    20d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Active, not recruiting, University of Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    23d
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • daretabart (hu1418K322A)